These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease. Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870 [TBL] [Abstract][Full Text] [Related]
3. Soluble HLA-G molecules are increased in lymphoproliferative disorders. Sebti Y; Le Friec G; Pangault C; Gros F; Drénou B; Guilloux V; Bernard M; Lamy T; Fauchet R; Amiot L Hum Immunol; 2003 Nov; 64(11):1093-101. PubMed ID: 14602240 [TBL] [Abstract][Full Text] [Related]
4. Increased soluble serum HLA class I antigens in patients with lymphoma. Nocito M; Montalbán C; González-Porque P; Villar LM Hum Immunol; 1997 Dec; 58(2):106-11. PubMed ID: 9475339 [TBL] [Abstract][Full Text] [Related]
5. Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Contini P; Ghio M; Poggi A; Filaci G; Indiveri F; Ferrone S; Puppo F Eur J Immunol; 2003 Jan; 33(1):125-34. PubMed ID: 12594841 [TBL] [Abstract][Full Text] [Related]
6. Expression of functional soluble human leucocyte antigen-G molecules in lymphoproliferative disorders. Sebti Y; Le Maux A; Gros F; De Guibert S; Pangault C; Rouas-Freiss N; Bernard M; Amiot L Br J Haematol; 2007 Jul; 138(2):202-12. PubMed ID: 17593027 [TBL] [Abstract][Full Text] [Related]
7. Adoptive immunotherapy for Hodgkin's lymphoma. Kennedy-Nasser AA; Bollard CM; Rooney CM Int J Hematol; 2006 Jun; 83(5):385-90. PubMed ID: 16787867 [TBL] [Abstract][Full Text] [Related]
8. Cell-mediated immunity in children with Hodgkin's and non-Hodgkin's lymphomas. Eckschlager T; Jira M; Strejcek J Pediatr Hematol Oncol; 1991; 8(3):251-6. PubMed ID: 1742184 [TBL] [Abstract][Full Text] [Related]
9. Cytotoxic protein expression in non-Hodgkin's lymphomas and Hodgkin's disease. Kanavaros P; Vlychou M; Stefanaki K; Rontogianni D; Gaulard P; Pantelidaki E; Zois M; Darivianaki K; Georgoulias V; Boulland ML; Gorgoulis V; Kittas C Anticancer Res; 1999; 19(2A):1209-16. PubMed ID: 10368677 [TBL] [Abstract][Full Text] [Related]
10. Human herpesvirus 6 in non-AIDS related Hodgkin's and non-Hodgkin's lymphomas. Torelli G; Marasca R; Montorsi M; Luppi M; Barozzi P; Ceccherini L; Batoni G; Bendinelli M; Muyombano A Leukemia; 1992; 6 Suppl 3():46S-48S. PubMed ID: 1318476 [No Abstract] [Full Text] [Related]
11. Epstein Barr virus (EBV) carrying cells in blood of Hodgkin's disease (HD) and non-Hodgkin lymphoma (NHL) patients with high antibody titers against EBV capsid antigens (VCA). Lewin N; Aman P; Mellstedt H; Carenfelt C; Klein G; Klein E Anticancer Res; 1990; 10(5A):1213-6. PubMed ID: 2173472 [TBL] [Abstract][Full Text] [Related]
12. T-cell subsets in peripheral blood of patients with newly diagnosed and posttreatment Hodgkin's and non-Hodgkin's lymphomas. Analysis by monoclonal antibody staining and flow cytometry. De Angelis P; Kimmel M; Lacher M; Filippa D; Melamed MR Anal Quant Cytol Histol; 1988 Aug; 10(4):235-42. PubMed ID: 2971365 [TBL] [Abstract][Full Text] [Related]
13. Dimerization of soluble HLA-G by IgG-Fc fragment augments ILT2-mediated inhibition of T-cell alloresponse. Zhong M; Weng X; Liang Z; Lu S; Li J; Chen X; Li Q; Sun W; Song Y; Shen G; Wu X Transplantation; 2009 Jan; 87(1):8-15. PubMed ID: 19136885 [TBL] [Abstract][Full Text] [Related]
14. [Differential diagnostic and prognostic value of serum cytokines (soluble CD30, soluble interleukin-2 receptor, interleukin-10 and interleukin-6) in Hodgkin's disease and lymphosarcomas]. Iaguzhinskaia OE; Lazarev IE; Nikitin EA; Samoĭlova RS; Loginova IV; Gemdzhan EG; Novikov VA; Mamiliaeva ZKh; Pivnik AV Ter Arkh; 2001; 73(4):45-51. PubMed ID: 11494447 [TBL] [Abstract][Full Text] [Related]
15. Natural killer clones recognize specific soluble HLA class I molecules. Carbone E; Terrazzano G; Colonna M; Tuosto L; Piccolella E; Franksson L; Palazzolo G; Pérez-Villar JJ; Fontana S; Kärre K; Zappacosta S Eur J Immunol; 1996 Mar; 26(3):683-9. PubMed ID: 8605938 [TBL] [Abstract][Full Text] [Related]
16. Increased number of functionally defective large granular lymphocytes in lymphoma patients. Muhonen T; Teerenhovi L; Saksela E Nat Immun Cell Growth Regul; 1987; 6(2):57-64. PubMed ID: 3600676 [TBL] [Abstract][Full Text] [Related]
17. Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Morandi F; Levreri I; Bocca P; Galleni B; Raffaghello L; Ferrone S; Prigione I; Pistoia V Cancer Res; 2007 Jul; 67(13):6433-41. PubMed ID: 17616704 [TBL] [Abstract][Full Text] [Related]
18. HLA class II polymorphism in Egyptian children with lymphomas. Al-Tonbary Y; Abdel-Razek N; Zaghloul H; Metwaly S; El-Deek B; El-Shawaf R Hematology; 2004 Apr; 9(2):139-45. PubMed ID: 15203870 [TBL] [Abstract][Full Text] [Related]
19. Leucocyte zinc in non-Hodgkin's lymphoma and Hodgkin's disease. Field HP; Jones R; Walker BE; Kelleher J; Simmons AV Nutr Cancer; 1988; 11(2):83-92. PubMed ID: 3362723 [TBL] [Abstract][Full Text] [Related]
20. Checkpoint Inhibition in Non-Hodgkin's Lymphoma. Heß G Oncol Res Treat; 2017; 40(11):662-672. PubMed ID: 29065421 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]